Citi Starts Halozyme Therapeutics (HALO) at Buy
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $109.66 --0%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 22
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 22
Join SI Premium – FREE
Citi initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $15.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Citi resumes Barrick Mining coverage with Neutral rating, $45 target
- Jones Trading Starts JFB Construction (JFB) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
